Remestemcel-L Clinical and Potency Studies Presented at Premier Meeting of Transplantation Research and Therapy
NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that two studies on the remestemcel-L development program for the treatment of …